SCHEMBL1574467

SCHEMBL1574467

COC(=O)c1cccc(NC(=O)N2CC(N(C)C)C2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.52
ALDH1A1 P00352 4/20 0.51
LMNA P02545 1/20 0.51
NPC1 O15118 4/20 0.50
MAPT P10636 3/20 0.48
HPGD P15428 2/20 0.48
EPHX2 P34913 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 1/20 0.47
RHOA P61586 1/20 0.47
FAAH O00519 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574592 0.87 RAB9A (0.53) RAB9AALDH1A1LMNANPC1HPGD
SCHEMBL1574699 0.87 RAB9A (0.49) RAB9AALDH1A1LMNANPC1MAPT
SCHEMBL1574383 0.87 L3MBTL1 (0.50) RAB9AALDH1A1LMNANPC1MAPT
SCHEMBL1574713 0.85 RAB9A (0.47) RAB9AALDH1A1LMNANPC1MAPT
SCHEMBL1575148 0.85 RAB9A (0.47) RAB9AALDH1A1LMNANPC1MAPT
SCHEMBL1575708 0.84 CASR (0.53) RAB9AALDH1A1LMNANPC1MAPT
SCHEMBL1575561 0.82 RAB9A (0.50) RAB9AALDH1A1LMNAMAPTHPGD
SCHEMBL1574971 0.82 ALDH1A1 (0.63) RAB9AALDH1A1LMNANPC1MAPT
SCHEMBL1575047 0.81 CYP2D6 (0.55) ALDH1A1NPC1MAPTSMN1; SMN2CYP1A2
SCHEMBL1574407 0.81 ALDH1A1 (0.62) RAB9AALDH1A1NPC1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB RAB9A 898/4885ALDH1A1 1445/4885LMNA 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.